title: Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors.
authors.affiliation: Department of Medical Oncology, National Center for Tumor Diseases (NCT).
authors.forename: S
authors.initials: S
authors.lastname: Zschäbitz
authors.affiliation: Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Lasitschka
authors.affiliation: Department of Medical Oncology, National Center for Tumor Diseases (NCT).
authors.forename: D
authors.initials: D
authors.lastname: Jäger
authors.affiliation: Department of Medical Oncology, National Center for Tumor Diseases (NCT) carsten.gruellich@med.uni-heidelberg.de.
authors.forename: C
authors.initials: C
authors.lastname: Grüllich
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000494:pharmacology / Q000627:therapeutic use*; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000077594:Nivolumab; D010984:Platinum / Q000627:therapeutic use; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D013736:Testicular Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074322:Antineoplastic Agents, Immunological; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; D010984:Platinum; C582435:pembrolizumab; D002945:Cisplatin